Carnegie advised Danmarks Eksport- og Investeringsfond (“EIFO”) in the sale of 1,921,466 shares at a price of DKK 260 per share, corresponding to approximately DKK 500m, in Zealand Pharma A/S. The shares were sold through an accelerated book building to Danish and international institutional investors.
Following the sale, EIFO no longer hold any shares in Zealand Pharma.